The devices are designed for vaccine immunizations. PharmaJet, which has an ongoing deal to use its devices in the World Health Organization’s efforts to eradicate polio, touts that the Tropis device enables mass-scale fractional dose poliovirus vaccine dosing at a lower total cost compared to intramuscular injections.
“The aim of this partnership is to provide access to this unique needle-free injection technology, to more patients – particularly in the emerging world where outbreaks typically occur, and availability and cost can be a barrier to vaccinations,” Mundipharma CEO Raman Singh said in prepared remarks.
“This includes addressing the shortage-driven need for easy-to-use, fractional dose inactivated poliovirus vaccine (fIPV) intradermal delivery systems. Distributing PharmaJet’s needle-free technology aligns well with our aim to provide access to innovative, cost-effective, and safe solutions for the healthcare providers and patients who need it the most,” Singh added.
“Mundipharma’s global network provides the commercial expertise to broaden and accelerate our expansion of needle-free devices within emerging markets,” PharmaJet chairman & CEO Ron Lowy said. “We look forward to working together to drive our efforts with health ministries to improve polio, MMR and influenza vaccinations across the emerging world.”